NCT05712304

Brief Summary

.Studies have demonstrated that the second examination of the proximal colon can significantly increase the proximal ADR.This study aimed to determine the impact of second examination of the proximal colon on AMR compared to conventional examination.Consecutive patients aged 40-75years undergoing colonoscopy for screening.Tandem withdrawal was used in the proximal colon.Patients were randomly assigned to either the second examination(SE) or the conventional examination(CE) group.The primary outcome measure was proximal AMR,defined as the number of proximal adenomas detected in the second pass(CE group)or the third pass(SE group)divided by the total number of proximal adenomas detected during the tandem colonoscopy.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
420

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Feb 2023

Typical duration for not_applicable

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 25, 2023

Completed
9 days until next milestone

First Posted

Study publicly available on registry

February 3, 2023

Completed
12 days until next milestone

Study Start

First participant enrolled

February 15, 2023

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 15, 2024

Completed
15 days until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2024

Completed
Last Updated

February 16, 2023

Status Verified

February 1, 2023

Enrollment Period

1.8 years

First QC Date

January 25, 2023

Last Update Submit

February 15, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • proximal AMR

    the number of proximal adenomas detected in the second pass(CE group)or the third pass(SE group)divided by the total number of proximal adenomas detected during the tandem colonoscopy.

    2 years

Secondary Outcomes (5)

  • proximal polyp miss rate

    2 years

  • Per-patient proximal AMR or per-patient proximal PMR

    2 years

  • The adenoma detection rate (ADR) or polyp detection rate (PDR)

    2 years

  • Adenoma per colonoscopy (APC) or polyp per colonoscopy (PPC)

    2 years

  • proximal advanced AMR(AAMR)

    2 years

Study Arms (2)

conventional examination

NO INTERVENTION

For patients in the CE group, the colonoscope was withdrawn directly from the splenic flexure to the rectum, and polyps that were found were removed

second examination

EXPERIMENTAL

For patients in the SE group, the colonoscope was reinserted into the cecum, additional polyps were removed from the proximal colon during the third withdrawall(third pass), and the remainder of the colon from splenic flexure to rectum was examined in a standard manner

Diagnostic Test: second examination of the proximal colon

Interventions

For patients in the SE group, the colonoscope was reinserted into the cecum, additional polyps were removed from the proximal colon during the third withdrawall(third pass), and the remainder of the colon from splenic flexure to rectum was examined in a standard manner

second examination

Eligibility Criteria

Age40 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Consecutive patients aged 40-75years undergoing colonoscopy for screening

You may not qualify if:

  • failed cecal intubation, prior colorectal resection, inadequate bowel preparation quality (Boston Bowel Preparation Scale (BBPS)scores \< 2 in any segment of the colon), inflammatory bowel disease or intestinal tuberculosis, familial polyposis syndrome, coagulation dysfunction, or polyp retrieval failure.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Second People's Hospital of Jingdezhen City

Jingdezhen, Jiangxi, 333000, China

RECRUITING

Third People's Hospital of Jingdezhen City

Jingdezhen, Jiangxi, 333000, China

RECRUITING

Study Officials

  • li yang

    Third People's Hospital of Jingdezhen,

    STUDY DIRECTOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 25, 2023

First Posted

February 3, 2023

Study Start

February 15, 2023

Primary Completion

December 15, 2024

Study Completion

December 30, 2024

Last Updated

February 16, 2023

Record last verified: 2023-02

Data Sharing

IPD Sharing
Will not share

Locations